[go: up one dir, main page]

WO2005089067A3 - Criblage de medicaments antiviraux et de compositions pharmaceutiques contenant des derives de thiazolidinone - Google Patents

Criblage de medicaments antiviraux et de compositions pharmaceutiques contenant des derives de thiazolidinone Download PDF

Info

Publication number
WO2005089067A3
WO2005089067A3 PCT/IL2005/000335 IL2005000335W WO2005089067A3 WO 2005089067 A3 WO2005089067 A3 WO 2005089067A3 IL 2005000335 W IL2005000335 W IL 2005000335W WO 2005089067 A3 WO2005089067 A3 WO 2005089067A3
Authority
WO
WIPO (PCT)
Prior art keywords
gag
gbvp
screening
pharmaceutical compositions
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2005/000335
Other languages
English (en)
Other versions
WO2005089067A2 (fr
Inventor
Paul Gregor
Nicholas Harris
Regina Zhuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rimonyx Pharmaceuticals Ltd
Original Assignee
Rimonyx Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rimonyx Pharmaceuticals Ltd filed Critical Rimonyx Pharmaceuticals Ltd
Priority to EP05718908A priority Critical patent/EP1738170A2/fr
Priority to US10/594,080 priority patent/US20070179137A1/en
Publication of WO2005089067A2 publication Critical patent/WO2005089067A2/fr
Anticipated expiration legal-status Critical
Publication of WO2005089067A3 publication Critical patent/WO2005089067A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé de criblage de petites molécules organiques qui inhibent directement l'interaction de glycosaminoglycanes (GAG) avec des protéines virales se liant aux GAG (GBVP). Ce procédé consiste à mettre en contact un GAG avec une GBVP en présence d'au moins un composé candidat, et à mesurer la quantité de GAG lié à la GBVP ou la quantité de GBVP liée au GAG. Une diminution significative de liaison GAG-GBVP comparée à la liaison GAG-GBVP en l'absence du composé candidat permet d'identifier ce composé en tant qu'inhibiteur de l'interaction GAG-GBVP. Cette invention concerne également des compositions pharmaceutiques comprenant certains dérivés de 2-thioxo-thiazolidinone particulièrement utiles contre des infections virales.
PCT/IL2005/000335 2004-03-24 2005-03-24 Criblage de medicaments antiviraux et de compositions pharmaceutiques contenant des derives de thiazolidinone Ceased WO2005089067A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05718908A EP1738170A2 (fr) 2004-03-24 2005-03-24 Criblage de medicaments antiviraux et de compositions pharmaceutiques contenant des derives de thiazolidinone
US10/594,080 US20070179137A1 (en) 2004-03-24 2005-03-24 Screening of anti-viral drugs and pharmaceuticals composition containing thiazolidinone derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55566704P 2004-03-24 2004-03-24
US60/555,667 2004-03-24

Publications (2)

Publication Number Publication Date
WO2005089067A2 WO2005089067A2 (fr) 2005-09-29
WO2005089067A3 true WO2005089067A3 (fr) 2009-04-23

Family

ID=34994124

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IL2005/000336 Ceased WO2005089068A2 (fr) 2004-03-24 2005-03-24 Compositions pharmaceutiques comprenant des derives de quinazolinecarboxamide anti-inflammatoires
PCT/IL2005/000335 Ceased WO2005089067A2 (fr) 2004-03-24 2005-03-24 Criblage de medicaments antiviraux et de compositions pharmaceutiques contenant des derives de thiazolidinone

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IL2005/000336 Ceased WO2005089068A2 (fr) 2004-03-24 2005-03-24 Compositions pharmaceutiques comprenant des derives de quinazolinecarboxamide anti-inflammatoires

Country Status (3)

Country Link
US (1) US20070179137A1 (fr)
EP (2) EP1740176A2 (fr)
WO (2) WO2005089068A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2727651C (fr) * 2008-06-17 2016-04-05 Priscille Brodin Composes anti-infectieux
WO2011160024A2 (fr) * 2010-06-17 2011-12-22 Fuzians Biomedicals, Inc. Composés utiles en tant qu'agents antiviraux, compositions, et procédés d'utilisation
EP3563682A1 (fr) 2011-08-08 2019-11-06 California Institute of Technology Utilité de nématodes à petites molécules
CN109748910B (zh) * 2018-12-17 2021-04-30 徐州医科大学 一种喹唑啉酮类化合物、其制备方法及医药用途
EP3969460A4 (fr) 2019-05-17 2023-03-08 California Institute Of Technology Dérivés d'ascaroside et procédés d'utilisation
CN118465272B (zh) * 2019-12-04 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
AU2022341967A1 (en) * 2021-09-07 2024-05-16 Gismo Therapeutics, Inc. Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interactions with glycosaminoglycans, methods of treatment, and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201127B1 (en) * 1998-02-25 2001-03-13 Eli Lilly And Company Process for preparing benzyl-substituted rhodanine derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1237849A1 (fr) * 1999-11-05 2002-09-11 University College London Activateurs de la guanylate cyclase soluble
IL154306A0 (en) * 2003-02-05 2003-09-17 Rimonyx Pharmaceuticals Ltd Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201127B1 (en) * 1998-02-25 2001-03-13 Eli Lilly And Company Process for preparing benzyl-substituted rhodanine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARKS ET AL.: "Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors.", J. MED. CHEM., vol. 44, 2001, pages 2178 - 2187 *

Also Published As

Publication number Publication date
WO2005089068A3 (fr) 2006-07-27
WO2005089068A2 (fr) 2005-09-29
EP1740176A2 (fr) 2007-01-10
EP1738170A2 (fr) 2007-01-03
WO2005089067A2 (fr) 2005-09-29
US20070179137A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
WO2006091646A3 (fr) Inhibiteurs de mdm2, sous forme de petites molecules et utilisations de ces derniers
WO2008036168A3 (fr) Nouvelles petites molécules inhibitrices de mdm2 et leurs utilisations
WO2007048042A3 (fr) Inhibiteurs de petites molecules d'ensemble capside de vih-1
BRPI0713031B8 (pt) composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
WO2008054600A3 (fr) Compositions et procédés de biodétection par chimie à matrice d'acides nucléiques
WO2008115281A3 (fr) Composés de traitement d'infections virales
EP1597350A4 (fr) Molecules d'acide nucleique, polypeptides, anticorps et compositions les contenant utiles dans le traitement et la detection de l'infection imputable au virus de la grippe
CL2011000136A1 (es) Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c.
WO2008127364A3 (fr) Composés antiviraux et utilisation de ceux-ci
WO2006128138A3 (fr) Biodetection reposant sur la chimie a base de matrices d'acides nucleiques
WO2007092888A3 (fr) Inhibiteurs ns5b hcv
CL2007003565A1 (es) Compuestos derivados de piperidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion vih.
CL2007001325A1 (es) Compuestos derivados de biciclos, inhibidores de cept; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, entre otras enfermedades.
NO20090438L (no) Hepatit C virus inhibitorer
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
WO2007138116A3 (fr) Composition pharmaceutique pour traiter des infections virales et/ou des maladies tumorales par inhibition du repliement et de la décomposition des protéines
BRPI0818804A2 (pt) Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
CL2007003791A1 (es) Compuestos derivados de piperidina, inhibidores de la proteina quinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para inhibir el crecimiento celular anormal.
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
NO20076322L (no) Fungicidblandinger
WO2009008921A3 (fr) Virus de la grippe de type b dotés d'une sensibilité réduite aux inhibiteurs de la neuraminidase
WO2007084435A8 (fr) Procedes de traitement de l'hepatite c
WO2008073982A3 (fr) Composés de 5,6-dihydro-1h-pyridine-2-one
BRPI0516981A (pt) inibidores de mif
WO2006125207A3 (fr) Compositions et procedes permettant d'accroitre la stabilite d'un anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10594080

Country of ref document: US

Ref document number: 2007179137

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005718908

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005718908

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10594080

Country of ref document: US